REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Results & Progress
6

Finishing Semaglutide — Final Progress Report

Noel Chapman·about 2 months ago
Final progress report on Semaglutide after completing my full planned protocol. This was my first experience with this peptide and I approached it as a systematic experiment. Setup: I established a 2-week baseline period before starting, tracking all the same metrics I would track during the protocol. This gave me a solid comparison point. Results summary: net positive across recovery, sleep, and joint health metrics. The improvements were moderate rather than dramatic, which is exactly what I expected based on the published literature and realistic user reports. Best result: recovery between training sessions. I was consistently able to train at higher frequencies without accumulated fatigue. Over 12 weeks this added up to significantly more productive training volume. Most disappointing: I expected more impact on body composition based on some reports I had read. The effect was minimal for me, though I acknowledge my diet was only loosely controlled. Would I recommend Semaglutide? Yes, with caveats. Set realistic expectations, commit to at least 8 weeks, track your metrics, and get bloodwork. The people who are disappointed are usually the ones who expected too much too fast.

Comments (4)

Lake FrancisDEMO·about 2 months ago

I have been stacking Semaglutide with another peptide for the last 8 weeks and the combination has been notably better than either alone in my experience. The synergy makes sense given their complementary mechanisms. Happy to share my specific protocol if anyone is interested.

2
Shay FischerDEMO·about 2 months ago

Real talk: Semaglutide worked well for me but the cost is significant. For anyone considering it, I would suggest doing a proper cost-benefit analysis first. Calculate the total cost for a full protocol and honestly assess whether the expected benefits justify that investment.

3
Reese FrostDEMO·about 2 months ago

Interesting data. My Semaglutide experience was somewhat different — I noticed effects earlier than you did, probably because I started at a higher initial dose. Trade-off was more pronounced side effects in week 1 that resolved by week 2. Neither approach is wrong, just different risk-reward profiles.

4
Shiloh ChambersDEMO·about 2 months ago

This thread has been incredibly helpful for understanding Semaglutide. I have been on the fence about starting for months and reading detailed real-world experiences like these has been more useful than any blog post or article I have found. The fact that most reports here are moderate rather than extreme actually increases my confidence.

5

Sign in to comment.